Date: 2011-10-28
Type of information: Licensing agreement
Compound: multimeric TNF superfamily ligands (TNFSFs)
Company: Topotarget (Denmark) Multimeric Biotherapeutics (USA)
Therapeutic area:
Type agreement: licensing
Action mechanism:
Disease:
Details: Topotarget and Multimeric Biotherapeutics announced the signature of an exclusive license agreement granting Multimeric rights to the further development of the multimeric TNF superfamily ligands (TNFSFs) for all therapeutic uses. TNFSFs are not a core activity of Topotarget IP assets. Topotarget continue to focus efforts on its lead compound the HDACi belinostat. Under the agreement, Multimeric will license the rights to all multimeric fusion proteins containing TNFSFs which are covered by Topotarget’s issued and pending patents in Europe, US, Canada, Japan, Australia, South Korea, and other territories. The agreement also grants Multimeric the rights to sub-license. No details on the terms of the agreement were disclosed.
Financial terms:
Latest news:
